• 1
    Valent P, Horny H-P, Li CY, et al. Mastocytosis. In: JaffeES, HarrisNL, SteinH, VardimanJW, editors. WHO classification of tumours. Pathology and genetics of tumours of the haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001. p 291304.
  • 2
    Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol 2002;127:140.
  • 3
    Travis WD, Li C-Y, Yam LT, Bergstralh EJ, Swee RG. Significance of systemic mast cell disease with associated hematologic disorders. Cancer 1988;62:965972.
  • 4
    Giebel LB, Strunk KM, Holmes SA, Spritz RA. Organization and nucleotide sequence of the human KIT (mast/stem cell growth factor receptor) proto-oncogene. Oncogene 1992;7:22072217.
  • 5
    Taylor ML, Metcalfe DD. Kit signal transduction. Hematol Oncol Clin North Am 2000;14:517535.
  • 6
    Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD. Demonstration of the origin of human mast cells from CD 34+ bone marrow progenitor cells. J Immunol 1991;146:14101415.
  • 7
    Ferger F, Dumas AR, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002;127:110114.
  • 8
    Tsujimura T, Furitsu T, Morimoto M, et al. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 1994;83:26192626.
  • 9
    Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:17361744.
  • 10
    Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ. The c-kit mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002;99:17411744.
  • 11
    Worobec AS, Semere T, Nagata H, Metcalfe DD. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer 1998;83:21202129.
  • 12
    Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in the peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995;92:1056010564.
  • 13
    Sperr WR, Walchshoper S, Horny H-P, et al. Systemic mastocytosis associated with acute myeloid leukemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. Br J Hematol 1998;103:740749.
  • 14
    Beghini A, Cairoli R, Morra E, Larizza L. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent c-kit mutation. Blood Cells Mol Dis 1998;24:262270.
  • 15
    Pullarkat VA, Pullarkat ST, Calverley DC, Brynes RK. Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His. Am J Hematol 2000;65:307309.
  • 16
    Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603625.
  • 17
    Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999;154:5360.
  • 18
    Valent P, Sperr WR, Samorapoompichit P, Geissler K, Lechner K, Horny H-P, Bennett JM. Myelomastocytic overlap syndromes: biology, criteria and relationship to mastocytosis. Leuk Res 2001;25:595602.
  • 19
    Sperr WR, Horny H-P, Lechner K, Valent P. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma 2000;37:473486.
  • 20
    Smith JD, Lazarchick J. Systemic mast cell disease with marrow and splenic involvement associated with chronic myelomonocytic leukemia. Leuk Lymphoma 1999;32:391394.
  • 21
    Sotlar K, Marafioti T, Griesser H, et al. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukemia. J Clin Pathol Mol Pathol 2000;53:188193.
  • 22
    Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730737.
  • 23
    Jordan CT. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia 2002;16:559562.
  • 24
    Ashman LK, Ferrao P, Cole SR, Cambareri AC. Effects of mutant c-kit in early myeloid cells. Leuk Lymphoma 1999;34:451461 [Corrected and republished. Leuk Lymphoma 2000;37:233–243].
  • 25
    Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002;100:661665.
  • 26
    Stevens EC, Rosenthal NS. Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease. Am J Clin Pathol 2001;116:177182.
  • 27
    Tian Q, Frierson HF Jr, Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999;154:16431647.
  • 28
    Wong KF, Chan JKC, Chan JCW, Kwong YL, Ma SK, Chow TC. Concurrent acute myeloid leukemia and systemic mastocytosis. Am J Hematol 1991;28:243244.
  • 29
    Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:10521056.
  • 30
    Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925932.
  • 31
    Longley BJ, Ma Y, Carter E, McMahon G. New approaches to therapy for mastocytosis. Hematol Oncol Clin North Am 2000;14:689695.
  • 32
    Ma Y, Carter E, Wang X, Shu C, McMahon G, Longley BJ. Indoline derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells. J Invest Dermatol 2000;114:392394.